Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 34.6 | 43.1 | 43.7 | 40.1 | 42.0 | 44.3 | 48.2 | 50.0 |
| Operating profit | $bn | 8.05 | 7.35 | ||||||
| Net profit | $bn | 4.5 | 7.1 | 6.9 | 5.7 | 13.4 | 6.5 | 4.7 | 9.6 |
| EPS reported | $ | 3.72 | 2.70 | ||||||
| Operating cashflow per share | $ | 5.48 | 5.09 | ||||||
| Capex per share | $ | 1.24 | 1.21 | ||||||
| FCF per share | $ | 4.23 | 3.89 | ||||||
| Free cash flow | $bn | 7.40 | 6.76 | ||||||
| Net debt | $bn | 5.2 | 26.9 | ||||||
| Book value equity | $bn | 52.1 | 51.0 | ||||||
| Book value per share | $ | 29.84 | 29.36 | ||||||
| Number of shares | m | 1,747 | 1,738 | ||||||
| DPS (TTM paid) | $ | 2.36 | 2.52 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 33.68 | 40.48 | ||||||
| P/B LTM | x | 4.20 | 3.71 | ||||||
| P/S LTM | x | 4.94 | 3.92 | ||||||
| P/FCF LTM | x | 29.60 | 28.01 | ||||||
| EV/EBITDA LTM | x | 18.91 | 22.26 | ||||||
| EV/Sales LTM | x | 5.09 | 4.48 | ||||||
| Earnings Yield LTM | % | 2.97% | 2.47% | ||||||
| FCF Yield | % | 3.38% | 3.57% | ||||||
| Quality | |||||||||
| ROE | % | 12.51% | 9.11% | ||||||
| ROIC | % | 8.43% | 5.61% | ||||||
| Operating margin | % | 18.16% | 15.24% | ||||||
| Gross margin | % | 55.51% | 57.12% | ||||||
| FCF/Sales | % | 16.68% | 14.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -51.31% | -66.17% | ||||||
| Sales Growth YoY | % | +5.67% | +10.00% | ||||||
| Net Income Growth YoY | % | -51.32% | -66.37% | ||||||
| FCF Growth | % | +16.44% | -2.31% | ||||||
| Operating Profit Growth | % | +17.92% | -5.60% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.88% | 2.31% | ||||||
| Dividend Growth | % | +7.27% | +6.78% | ||||||
| Payout Ratio | % | 63.33% | 63.09% | ||||||
| FCF/Debt | x | 0.49 | 0.22 | ||||||
| Net Debt/EBITDA | x | 0.55 | 2.79 | ||||||
| EBIT/Net interest | x | 23.60 | 8.26 | ||||||
| Net debt/market cap | % | 2.37% | 14.19% | ||||||
| Net debt/Equity | x | 0.10 | 0.53 | ||||||
| Gross debt/equity | x | 0.29 | 0.61 | ||||||
ETFs that hold Abbott Laboratories
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Schwab U.S. Dividend Equity ETF | SCHD | 6 | 4.04% |
| State Street Health Care Select Sector SPDR ETF | XLV | 9 | 2.93% |
| Vanguard Health Care ETF | VHT | 9 | 2.40% |
| iShares U.S. Healthcare ETF | IYH | 9 | 2.77% |
| iShares U.S. Medical Devices ETF | IHI | 1 | 17.66% |
| Fidelity MSCI Health Care Index ETF | FHLC | 9 | 2.56% |
| iShares S&P 500 Health Care Sector UCITS ETF | IUHC.L | 9 | 2.93% |
| Harvest Healthcare Leaders Income ETF | HHL.TO | 4 | 5.01% |
| Xtrackers MSCI USA Health Care UCITS ETF 1D | XUHC.L | 9 | 2.94% |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc) | SXLV.L | 9 | 2.93% |
Funds with Abbott Laboratories among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Schwab U.S. Dividend Equity ETF | SCHD | 6 | 4.04% |
| State Street Health Care Select Sector SPDR ETF | XLV | 9 | 2.93% |
| Vanguard Health Care ETF | VHT | 9 | 2.40% |
| iShares U.S. Healthcare ETF | IYH | 9 | 2.77% |
| iShares U.S. Medical Devices ETF | IHI | 1 | 17.66% |
| Fidelity MSCI Health Care Index ETF | FHLC | 9 | 2.56% |
| iShares S&P 500 Health Care Sector UCITS ETF | IUHC.L | 9 | 2.93% |
| Harvest Healthcare Leaders Income ETF | HHL.TO | 4 | 5.01% |
| Xtrackers MSCI USA Health Care UCITS ETF 1D | XUHC.L | 9 | 2.94% |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc) | SXLV.L | 9 | 2.93% |
Funds with Abbott Laboratories among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free